Posted by Michael Wonder on 08 Feb 2022
Leqvio therapy to lower cholesterol approved by FDA, IVX Health now accepting new Leqvio patients
8 February 2022 - IVX Health, a national provider of infusion and injection therapy for patients with complex chronic conditions, announced today the expansion of its injection formulary with the addition of Leqvio (inclisiran), a new FDA approved therapy by Novartis indicated for the treatment of adult patients with clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolaemia who require additional LDL-cholesterol lowering.
IVX Health is currently accepting referrals for Leqvio patients in its over 50 infusion centres across the nation.
